Companies unite to advance non-viral CRISPR cell engineering

Gene editing

Indee Labs and GenScript have formed a research collaboration with the aim to develop a DNA knock-in kit for Hydropore to enable large transgene inserts above the 5kb limit for AAV. 

As part of the collaboration, GenScript will provide a variety of single-strand and double-strand (ssDNA and dsDNA) constructs for direct DNA inserts, while the team at Indee Labs will optimise the Hydropore protocol and evaluate the functional differences between T cells processed with Hydropore and electroporation.  

Looking ahead, the companies will work on co-marketing a complete non-viral solution to the gene and cell therapy community.  

“GenScript is pleased to partner with Indee Labs to advance the development of novel RNP and oligo delivery systems for non-viral CRISPR cell engineering,” said Ray Chen, PhD, president of GenScript’s Life Science Group. 

The collaboration hopes to empower scientists to insert large transgenes (>5 kb) into immune cells and other cell types via Hydropore delivery of ssDNA and dsDNA constructs. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free